PROTAC PI3K/110β degrader-2
PROTAC PI3K/110β degrader-2 is a VHL-recruiting PI3K/110β PROTAC degrader, with DC50 values of 1.258 μM and 2.185 μM in MCF-7/ADM and A549/DDP cells, respectively. PROTAC PI3K/110β degrader-2 induces proteasomal degradation of PI3K/110β, inhibits phosphorylation of AKT and expression of Bcl-2, while suppressing the activity and expression of P-gp. It also induces endoplasmic reticulum stress and mitochondrial apoptosis via the PERK/CHOP pathway. PROTAC PI3K/110β degrader-2 exerts anti-tumor activity against multidrug-resistant cancer cells both in vitro and in vivo, and produces a synergistic effect when combined with Doxorubicin (HY-15142A) or Cisplatin (HY-17394), making it applicable for the research of multidrug-resistant cancers.
(Pink: PI3K ligand (HY-75124); Blue: VHL ligand (HY-125845); Black: linker (HY-W002042)).
For research use only. We do not sell to patients.
- CAS No.: 3070438-79-5
- Formula: C51H65N9O7S
- Molecular Weight:948.18
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
(Pink: PI3K ligand (HY-75124); Blue: VHL ligand (HY-125845); Black: linker (HY-W002042)).
IC50 & Target
[1]|
PI3K 1.258 μM (DC50, MCF-7/ADM) |
PI3K 2.185 μM (DC50, A549/DDP) |
Bax |
Bcl-2 |
Akt |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549/CDDP | DC50 |
2.19 μM
|
Half-maximal degradation of PI3K/p110β protein in human A549/DDP cells assessed via Western blot after 24 h treatment.
Half-maximal degradation of PI3K/p110β protein in human A549/DDP cells assessed via Western blot after 24 h treatment.
|
40294240 |
| A549 | IC50 |
85.2 μM
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
|
40294240 |
| A549/CDDP | IC50 |
39.23 μM
|
Antiproliferative activity against human A549/DDP cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
Antiproliferative activity against human A549/DDP cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
|
40294240 |
| MCF7 | IC50 |
53.99 μM
|
Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
|
40294240 |
| MCF7 | IC50 |
38.73 μM
|
Antiproliferative activity against human MCF-7/ADM cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
Antiproliferative activity against human MCF-7/ADM cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
|
40294240 |
| MCF7 | DC50 |
1.258 μM
|
Selective degradation of p110β protein in human MCF-7/ADM multidrug-resistant breast cancer cells.
Selective degradation of p110β protein in human MCF-7/ADM multidrug-resistant breast cancer cells.
|
40294240 |
| A549/CDDP | DC50 |
2.185 μM
|
Selective degradation of p110β protein in human A549/DDP multidrug-resistant lung cancer cells.
Selective degradation of p110β protein in human A549/DDP multidrug-resistant lung cancer cells.
|
40294240 |
| MCF7 | IC50 |
10.62 μM
|
Inhibition of cell viability in human MCF-7/ADM multidrug-resistant breast cancer cells incubated for 48 hrs by MTT assay.
Inhibition of cell viability in human MCF-7/ADM multidrug-resistant breast cancer cells incubated for 48 hrs by MTT assay.
|
40294240 |
| A549/CDDP | IC50 |
18.75 μM
|
Inhibition of cell viability in human A549/DDP multidrug-resistant lung cancer cells incubated for 48 hrs by MTT assay.
Inhibition of cell viability in human A549/DDP multidrug-resistant lung cancer cells incubated for 48 hrs by MTT assay.
|
40294240 |
In Vitro
PROTAC PI3K/110β degrader-2 (compound J-6) (2.5-25 μM) selectively degrades PI3K/p110β in MCF-7/ADM (DC50 = 1.26 μM) and A549/DDP (DC50 = 2.19 μM) cells in a time- and concentration-dependent manner via the proteasome and VHL E3 ligase pathways[1].
PROTAC PI3K/110β degrader-2 (24 h) exhibits potent dose-dependent anti-tumor activity in vitro, with an IC50 of 38.73 μM in multidrug-resistant MCF-7/ADM cells and an IC50 of 39.23 μM in A549/DDP cells[1].
PROTAC PI3K/110β degrader-2 (48 h) inhibits the viability of MCF-7/ADM cells and A549/DDP cells, with an IC50 of 10.62 μM against the former and 18.75 μM against the latter[1].
PROTAC PI3K/110β degrader-2 (6.25-25 μM; 24 h) inhibits the activity and expression of P-gp in MCF-7/ADM and A549/DDP cells, and exerts a strong synergistic anti-tumor effect with Cisplatin (HY-17394) in A549/DDP cells[1].
PROTAC PI3K/110β degrader-2 (0.25-25 μM; 24 h) alters the mRNA expression of pten, akt and bcl-2 in A549/DDP cells[1].
PROTAC PI3K/110β degrader-2 (6.25-100 μM; 24 h) inhibits the growth of A549/DDP cells, with a median effective dose of 38.203 μM[1].
PROTAC PI3K/110β degrader-2 (0.25-25 μM; 24 h) induces endoplasmic reticulum stress-mediated mitochondrial apoptosis in MCF-7/ADM and A549/DDP cells by activating the UPR signaling pathway and regulating proteins of the AKT/Bcl-2 pathway[1].
PROTAC PI3K/110β degrader-2 (6.25-25 μM; 24 h) dose-dependently induces the production of mitochondrial ROS in A549/DDP cells[1].
PROTAC PI3K/110β degrader-2 (25 μM; 24 h) reduces the mitochondrial membrane potential of A549/DDP cells[1].
PROTAC PI3K/110β degrader-2 (0.25-25 μM) regulates the expression of proteins related to apoptosis and the PI3K/AKT signaling pathway in A549/DDP cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549/DDP multidrug-resistant lung cancer cells
-
Concentration:25 μM
-
Incubation Time:24 h
-
Result:Increased pten、akt、bcl-2 mRNA expression in A549/DDP cells relative to untreated controls.
-
Cell Line:A549/DDP multidrug-resistant lung cancer cells
-
Concentration:6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM
-
Incubation Time:24 h
-
Result:Resulted in a growth inhibition in A549/DDP cells.
Achieved a median effect dose (Dm) of 38.203 μM, a dose-effect curve shape parameter (m) of 0.911, and a linear correlation coefficient (r) of 0.959.
-
Cell Line:A549/DDP multidrug-resistant lung cancer cells
-
Concentration:0.25, 2.5, 25 μM
-
Incubation Time:24 h
-
Result:Alters the mRNA expression of pten, akt and bcl-2.
Regulated the expression of proteins related to apoptosis and the PI3K/AKT signaling pathway.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:nude (implanted with MCF-7/ADM cells)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; once every other day; 7 doses
-
Result:Significantly reduced MCF-7/ADM xenograft tumor volume compared to the control group.
Effectively downregulated tumor tissue PI3K/110β level, with only a slight decrease in PI3K/110α levels.
Significantly increased tumor tissue expression of ATF6, CHOP, GRP78, and caspase-12, while slightly increasing P-PERK and P-IRE1 levels.
Significantly enhanced mitochondrial apoptosis markers cleaved-caspase-9 and Bax, while inhibiting cleaved-caspase-8 and Bcl-2.
Inhibited downstream PI3K signaling molecule p-AKT, with PTEN levels similar to controls.
Dramatically reduced P-gp expression in tumor tissues.
Caused no significant change in mouse body weight, with organ index, major organ hematoxylin and eosin staining, and serum biochemical parameters (PLT, WBC, LYM, ALT, AST, CR, BUN) all within normal ranges.
Chemical Information
-
CAS No. 3070438-79-5
-
Molecular Weight 948.18
-
Formula C51H65N9O7S
-
SMILES
O=C(NCC1=CC=C(C=C1)C2=C(N=CS2)C)[C@H]3N(C[C@@H](C3)O)C([C@H](C(C)(C)C)NC(CCCCCCNC(C4=CC=CC=C4NC(C)C5=CC(C)=CN6C5=NC(N7CCOCC7)=CC6=O)=O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)